Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy

It isn’t just the cutting-edge science. Novartis’ landmark approval also highlights regulatory and reimbursement innovation and also may set the rules that the next wave of cell and gene therapies have to follow.